CryoPort Inc (NASDAQ:CYRX) Shares Bought by Taylor Frigon Capital Management LLC

Taylor Frigon Capital Management LLC grew its position in CryoPort Inc (NASDAQ:CYRX) by 2.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 204,799 shares of the consumer goods maker’s stock after buying an additional 4,954 shares during the quarter. CryoPort accounts for about 2.7% of Taylor Frigon Capital Management LLC’s portfolio, making the stock its 2nd largest holding. Taylor Frigon Capital Management LLC owned about 0.66% of CryoPort worth $3,751,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of CYRX. BNP Paribas Arbitrage SA acquired a new position in shares of CryoPort in the 1st quarter valued at approximately $74,000. Metropolitan Life Insurance Co. NY increased its position in CryoPort by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,607 shares of the consumer goods maker’s stock worth $95,000 after purchasing an additional 6,722 shares in the last quarter. MML Investors Services LLC acquired a new position in CryoPort during the 4th quarter worth approximately $157,000. Bank of America Corp DE increased its position in CryoPort by 92.3% during the 4th quarter. Bank of America Corp DE now owns 16,037 shares of the consumer goods maker’s stock worth $176,000 after purchasing an additional 7,697 shares in the last quarter. Finally, Conestoga Capital Advisors LLC acquired a new position in CryoPort during the 1st quarter worth approximately $355,000. Institutional investors own 54.06% of the company’s stock.

CYRX stock traded up $0.33 during trading on Friday, reaching $20.00. 4,908 shares of the company were exchanged, compared to its average volume of 291,896. The company has a debt-to-equity ratio of 0.42, a current ratio of 11.57 and a quick ratio of 11.52. CryoPort Inc has a twelve month low of $8.28 and a twelve month high of $20.79. The business’s 50-day moving average is $18.71. The company has a market capitalization of $611.26 million, a P/E ratio of -63.77 and a beta of 0.85.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Thursday, May 2nd. The consumer goods maker reported ($0.08) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). CryoPort had a negative net margin of 41.61% and a negative return on equity of 28.30%. The firm had revenue of $6.65 million during the quarter, compared to analysts’ expectations of $6.56 million. During the same period in the prior year, the company posted ($0.10) EPS. The company’s revenue was up 65.4% on a year-over-year basis. As a group, research analysts forecast that CryoPort Inc will post -0.28 earnings per share for the current fiscal year.

CYRX has been the subject of a number of research analyst reports. BidaskClub upgraded shares of Zebra Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, July 6th. Svb Leerink reiterated an “outperform” rating on shares of CryoPort in a research report on Monday, July 15th. Needham & Company LLC reiterated a “buy” rating and set a $40.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Monday, July 1st. Leerink Swann initiated coverage on shares of CryoPort in a research report on Monday, July 15th. They set a “buy” rating and a $24.00 price objective for the company. Finally, B. Riley set a $6.00 price objective on shares of Intevac and gave the stock a “hold” rating in a research report on Friday, July 19th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $22.00.

CryoPort Profile

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

Read More: Moving Average Convergence Divergence (MACD)

Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort Inc (NASDAQ:CYRX).

Institutional Ownership by Quarter for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.